Linked Life Data

19807589

Source:http://linkedlifedata.com/resource/pubmed/id/19807589

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2009-10-7
pubmed:abstractText
This paper examines the rationale, utility and feasibility of including quality of life as an outcome measure in Phase I trials of new applications of chemotherapy drugs. Typically, Phase I trials in oncology are designed to assess safety and maximal tolerated dose; however, it is argued that when subjectively assessed, self perceived quality of life is as important as physical toxicity. The outcomes of studies that have applied quality-of-life assessment in Phase I trials are reviewed, and recommendations are made for future research based on both methodologic and practical considerations.
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:month
Oct
pubmed:issn
1744-8379
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
633-44
pubmed:year
2005
pubmed:articleTitle
Quality of life as an endpoint in Phase I oncology clinical trials of novel chemotherapy drugs.
pubmed:affiliation
University of Calgary, Department of Psychosocial Resources, ACB Holy Cross Site, 2202 2nd St., SW Calgary, Alberta, T2S 3C1, Canada. l.carlson@ucalgary.ca
pubmed:publicationType
Journal Article